CY1120332T1 - Μιμητικα καλσιτονινης για τη θεραπεια των ασθενειων και των διαταραχων - Google Patents
Μιμητικα καλσιτονινης για τη θεραπεια των ασθενειων και των διαταραχωνInfo
- Publication number
- CY1120332T1 CY1120332T1 CY20181100625T CY181100625T CY1120332T1 CY 1120332 T1 CY1120332 T1 CY 1120332T1 CY 20181100625 T CY20181100625 T CY 20181100625T CY 181100625 T CY181100625 T CY 181100625T CY 1120332 T1 CY1120332 T1 CY 1120332T1
- Authority
- CY
- Cyprus
- Prior art keywords
- reduce
- undesirable high
- kalsitonin
- medicines
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Περιγράφεται η χρήση ενός πεπτιδίου που έχει ΑΡ. ΤΑΥΤΟΤΗΤΑΣ ΑΛΛΗΛΟΥΧΙΑΣ: 18 για τη θεραπεία του διαβήτη τύπου I, του διαβήτη Τύπου 11, του μεταβολικού συνδρόμου ή της παχυσαρκίας ή για την καταστολή της πίεσης ή για την άμβλυνση της ανοχής στην ινσουλίνη ή για τη μείωση ενός ανεπιθύμητου υψηλού επιπέδου γλυκόζης στον ορό νηστείας ή για τη μείωση ενός ανεπιθύμητα υψηλού επιπέδου γλυκόζης στον ορό ή για τη μείωση ενός ανεπιθύμητα υψηλού επιπέδου ινσουλίνης στον ορό ή για τη μείωση μιας ανεπιθύμητα μεγάλης απόκρισης σε μια δοκιμασία ανοχής γλυκόζης.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554771P | 2011-11-02 | 2011-11-02 | |
| US201161578620P | 2011-12-21 | 2011-12-21 | |
| EP12846423.7A EP2773365B1 (en) | 2011-11-02 | 2012-11-02 | Peptide analogs for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120332T1 true CY1120332T1 (el) | 2019-07-10 |
Family
ID=51266018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100625T CY1120332T1 (el) | 2011-11-02 | 2018-06-14 | Μιμητικα καλσιτονινης για τη θεραπεια των ασθενειων και των διαταραχων |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP2773365B1 (el) |
| CY (1) | CY1120332T1 (el) |
| DK (2) | DK2773365T3 (el) |
| ES (2) | ES2586805T3 (el) |
| HR (1) | HRP20180903T1 (el) |
| HU (1) | HUE039105T2 (el) |
| LT (1) | LT3095484T (el) |
| PL (1) | PL3095484T3 (el) |
| PT (1) | PT3095484T (el) |
| RS (1) | RS57519B1 (el) |
| SI (1) | SI3095484T1 (el) |
| TR (1) | TR201808456T4 (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201704429D0 (en) * | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4764589A (en) * | 1987-05-26 | 1988-08-16 | Rorer Pharmaceutical Corporation | [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| EP2088188B1 (en) | 1997-04-16 | 2011-08-31 | Unigene Laboratories, Inc. | Direct expression of peptides into culture media |
| CN1329502A (zh) | 1998-12-04 | 2002-01-02 | 普罗瓦利斯英国有限公司 | 含有胰岛素的药物组合物 |
| CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| JP2006521366A (ja) | 2003-03-28 | 2006-09-21 | シグモイド・バイオテクノロジーズ・リミテッド | シームレスマイクロカプセルを含む固形経口剤形 |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| WO2005014031A1 (en) | 2003-07-23 | 2005-02-17 | Novartis Ag | Use of calcitonin in osteoarthritis |
| US20070172517A1 (en) | 2003-09-17 | 2007-07-26 | Ben-Sasson Shmuel A | Compositions capable of facilitation penetration across a biological barrier |
| US20080200563A1 (en) | 2004-07-22 | 2008-08-21 | Thiomatrix Forschungs- Und Beratungs- Gmbh | Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors |
| GB0422644D0 (en) * | 2004-10-12 | 2004-11-10 | Novartis Ag | Organic compounds |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| US8815583B2 (en) | 2005-06-24 | 2014-08-26 | Enteris Biopharma, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| ES2369244T3 (es) | 2006-03-13 | 2011-11-28 | Advancell Advanced In Vitro Cell Technologies,S.A. | Sistemas estables de nanocápsulas para la administración de moléculas activas. |
| EP2526950A1 (en) | 2006-04-07 | 2012-11-28 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| CA2750035C (en) * | 2009-01-22 | 2018-02-27 | Unigene Laboratories Inc. | Treatment for obesity |
| AU2010223329B2 (en) * | 2009-03-12 | 2016-07-21 | Keybioscience Ag | Treatment of diabetes and metabolic syndrome |
-
2012
- 2012-11-02 HU HUE16174260A patent/HUE039105T2/hu unknown
- 2012-11-02 DK DK12846423.7T patent/DK2773365T3/en active
- 2012-11-02 EP EP12846423.7A patent/EP2773365B1/en not_active Not-in-force
- 2012-11-02 SI SI201231314T patent/SI3095484T1/en unknown
- 2012-11-02 PT PT161742606T patent/PT3095484T/pt unknown
- 2012-11-02 TR TR2018/08456T patent/TR201808456T4/tr unknown
- 2012-11-02 RS RS20180695A patent/RS57519B1/sr unknown
- 2012-11-02 EP EP16174260.6A patent/EP3095484B1/en active Active
- 2012-11-02 ES ES12846423.7T patent/ES2586805T3/es active Active
- 2012-11-02 PL PL16174260T patent/PL3095484T3/pl unknown
- 2012-11-02 LT LTEP16174260.6T patent/LT3095484T/lt unknown
- 2012-11-02 EP EP18161594.9A patent/EP3357540A1/en not_active Withdrawn
- 2012-11-02 ES ES16174260.6T patent/ES2673617T3/es active Active
- 2012-11-02 DK DK16174260.6T patent/DK3095484T3/en active
-
2018
- 2018-06-11 HR HRP20180903TT patent/HRP20180903T1/hr unknown
- 2018-06-14 CY CY20181100625T patent/CY1120332T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2773365A1 (en) | 2014-09-10 |
| HUE039105T2 (hu) | 2018-12-28 |
| PL3095484T3 (pl) | 2018-10-31 |
| EP3357540A1 (en) | 2018-08-08 |
| EP3095484B1 (en) | 2018-05-02 |
| ES2586805T3 (es) | 2016-10-19 |
| DK2773365T3 (en) | 2016-08-29 |
| TR201808456T4 (tr) | 2018-07-23 |
| ES2673617T3 (es) | 2018-06-25 |
| EP2773365B1 (en) | 2016-07-20 |
| HRP20180903T1 (hr) | 2018-08-24 |
| RS57519B1 (sr) | 2018-10-31 |
| EP3095484A1 (en) | 2016-11-23 |
| DK3095484T3 (en) | 2018-06-25 |
| PT3095484T (pt) | 2018-06-20 |
| SI3095484T1 (en) | 2018-08-31 |
| EP2773365A4 (en) | 2015-05-20 |
| LT3095484T (lt) | 2018-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| CY1120030T1 (el) | Διπλοι glp1/gip ή τριγωνικοι αγωνιστες glp1/gip/ γλυκαγονης | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
| CY1119987T1 (el) | Παραγωγα εξενδινης-4 ως διττοι αγωνιστες glp1/γλυκαγονης | |
| CY1118616T1 (el) | Λιξισενατιδη ως προσθετη θεραπεια σε βασικη ινσουλινη σε διαβητη τυπου 2 | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| CY1115862T1 (el) | Θεραπεια με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια | |
| CY1117250T1 (el) | Λιξισενατιδη και μετφορμινη για τη θεραπευτικη αγωγη διαβητη τυπου 2 | |
| CL2015001241A1 (es) | Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) | |
| CY1116803T1 (el) | Φαρμακευτικος συνδυασμος για χρηση στον γλυκαιμικο ελεγχο σε ασθενεις με διαβητη τυπου 2 | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| NZ707139A (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| WO2013186240A3 (en) | Exendin-4 peptide analogues | |
| CY1119976T1 (el) | Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων | |
| CO6670520A2 (es) | Lactmas sustituidas con piperidinio como moduladores de gpr119 | |
| CY1119850T1 (el) | Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης | |
| MX351092B (es) | Analogos peptidicos para tratar enfermedades y trastornos. | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| WO2015063081A3 (en) | Micrornas modulating the effect of glucocorticoid signaling | |
| BR112014006587A2 (pt) | modulação antisense da expressão de gcgr | |
| AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
| WO2014036528A3 (en) | Agents useful for treating obesity, diabetes and related disorders |